- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00711373
Vascularized Composite Allotransplantation of the Hand (HandCTA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
At the Christine M. Kleinert Institute in Louisville, Kentucky, we are recruiting patients for a research protocol that is underway for Composite Tissue Allotransplantation of the Hand. This study is not for all upper extremity injuries, but it is a possibility for some.
The Hand Surgeons at Kleinert, Kutz and Associates and the Christine M. Kleinert Institute performed the first hand transplant in the United States. This patient is doing very well, and is now almost 15 years post transplant. We have also transplanted seven other recipients, including a bilateral recipient. For more information visit www.handtransplant.com.
While hand transplantation is a viable option for select upper extremity amputees, there are significant risks that must be understood before a patient can decide whether hand transplantation is the right option for him or her. The major risk is the systemic immunosuppression that all current hand transplant recipients must take.
As part of this clinical trial of hand transplanation we are also offering a sub-study sub study to determine if cells isolated from fat tissue can be used to control the immune response against the graft. This population of cells that will be isolated from fat tissue is called the stromal vascular fraction (SVF) and has been used on an experimental basis in patients who have problems with blood vessels in their legs, with patients who have received a bone marrow transplant, and with patients who have Chron's disease. These trials have also been experimental. To date, there have been no cases where the SVF cells isolated from and used in the same patient have been associated with harmful side effects.
In this optional sub-study SVF isolated from the patient's own fat tissue would be injected into the graft at the time of transplant, or at the time of a rejection episode. We hope that these cells will help the hand and the nerves heal, and help control your immune systems response against the donor hand. However, this is an experimental study and we don't know if this will work or not. After your transplant and the injection of the SVF cells you will be followed and treated the same as any other hand transplant recipient in this clinical trial.
This sub-study is optional. Subjects can choose to not participate in this sub-study and still be able to participate in the hand transplant clinical trial.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Tuna Ozyurekoglu, MD
- Phone Number: 502-561-0352
- Email: tozyurekoglu@cmki.org
Study Contact Backup
- Name: Donna Stacy, RN
- Phone Number: 502-562-0313
- Email: dstacy@cmki.org
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Kleinert Kutz and Associates/Jewish Hospital and St. Mary's Healthcare
-
Contact:
- Donna Stacy, RN
- Phone Number: 502-562-0313
- Email: dstacy@cmki.org
-
Principal Investigator:
- Chris Jones, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Candidates may be male or female patients between the ages of 18 and 65 who are missing all or part of a hand and forearm
- No serious co-existing medical or psycho-social problems
- Must be HIV negative at the time of transplant
- Crossmatch is negative between donor and recipient
- Women who are of child bearing potential must have a negative pregnancy test (urine test is acceptable) within 48 hours of transplant and agree to use reliable contraception for one year following transplant
- Subjects must give written informed consent
Exclusion Criteria:
- Uncontrolled infection or severe concomitant diseases which would exclude the recipient from transplantation
- Alcoholism not currently under control
- Malignancy
- Excessive proximal level of amputation: some presence of proximal muscles is required to motor a functioning hand
- Congenital Abnormalities: co-existent absence/atrophy/agenesis of any tissue may affect post transplant results
- History of amputation of less than six months: subject must be allowed to attempt prosthetic use prior to hand transplantation
- Blindness: blind amputees may be poor candidates because sensory return in the hand may not provide sufficient protective sensation
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Unilateral and Bilateral Amputees
|
Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
functioning allograft
Time Frame: Monthly functional analysis for first three months and then on an annual basis for the life of the graft
|
Subjects will be monitored in Louisville for three months.
After that subject will be monitored for function of the allograft on an annual basis or as clinical course indicates.
We are requesting that subjects allow function to be evaluated on an annual basis for the life of the graft.
|
Monthly functional analysis for first three months and then on an annual basis for the life of the graft
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
document and manage complications associated with Composite Tissue allotransplantation
Time Frame: monthly labs for the first year, then bi-monthly for the first five years, or as clincial course indicates
|
Transplant recipients will have drug levels drawn weekly and then monthly until target blood levels of immunosuppression are acheived.
We will then have blood drawn monthly and then quarterly as time progresses.
We are requesting that subjects allow us to follow them for the life of the graft.
|
monthly labs for the first year, then bi-monthly for the first five years, or as clincial course indicates
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Chris Jones, MD, Jewish Hospital Transplant Center
- Principal Investigator: Tuna Ozyurekoglu, MD, Christine M. Kleinert Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 192.98
- DoD-OAR A-14022.5
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Extremity Injuries
-
Hacettepe UniversityCompletedUpper Extremity InjuriesTurkey
-
Postgraduate Institute of Medical Education and...CompletedUpper Extremity Injury Trauma
-
Beijing Jishuitan HospitalCompletedUpper Extremity Injury TraumaChina
-
Massachusetts General HospitalTerminatedAcute Injury of Upper Extremity
-
Massachusetts General HospitalEnrolling by invitationUpper Extremity Fractures | Upper Extremity Non-Fracture Bone and Joint Conditions
-
MediWound LtdUnknownBurns, Upper Extremity | Burns, Lower ExtremitySlovakia
-
Hacettepe UniversityNot yet recruitingAthletic Injuries | Image | Upper Extremity
-
McGill University Health Centre/Research Institute...University of ChileUnknown
-
Medical University of ViennaCompleted
-
University of Kansas Medical CenterUnknownUpper Extremity Injuries | Elbow Injuries | Sprain Ulnar Collateral Ligament | Strain of Ulnar Collateral Ligament | Complete Tear Ulnar Collateral LigamentUnited States
Clinical Trials on Allogeneic hand transplantation
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedAcute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Plasma Cell Myeloma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Minimal Residual Disease | Therapy-Related Acute Myeloid Leukemia | Therapy-Related Myelodysplastic... and other conditionsUnited States
-
Emory UniversityTerminatedAmputation | TransplantationUnited States
-
Wake Forest University Health SciencesCompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell NeoplasmUnited States
-
Southern Illinois UniversityMemorial Medical Center; Memorial Medical Center FoundationCompletedTraumatic Amputation of Arm | Traumatic Amputation of HandUnited States
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
University of PittsburghU.S. Army Medical Research and Development Command; San Antonio Military Medical... and other collaboratorsTerminated
-
University Hospital, BordeauxActive, not recruitingMyelodysplastic SyndromesFrance
-
Hospital Universitario La PazUniversity of MalagaRecruitingTransplant-Related DisorderSpain
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedHematological MalignanciesUnited States